Аллергический ринит. Возможности превентивной терапии


А.Ю. Насунова, О.С. Дробик

Аллергический ринит является серьезной медико-социальной проблемой, связанной с неуклонно возрастающим уровнем заболеваемости и высокими экономическими затратами здравоохранения. Проведенные исследования продемонстрировали целесообразность применения назальных глюкортикостероидов, в т. ч. в качестве превентивной терапии, пациентами, страдающими среднетяжелыми и тяжелыми проявлениями сезонного аллергического ринита, т. к. они обладают высокой степенью избирательности воздействия на воспалительных каскад, что приводит к стойкому клиническому улучшению.

Литература



1. Meltzer EO, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc


2009;30(3):244–54.


2. Nathan RA. The burden of allergic rhinitis. Allergy


Asthma Proc 2007;28(1):3–9.


3. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis.


J Allergy Clin Immunol 2010;125(2 Suppl. 2):


103–15.


4. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy


2008;63(10):1292–300.


5. Wallace DV, et al. Joint Task Force on Practice; American Academy of Allergy; Asthma & Immunology; American College of Allergy; Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: an updated




лиТЕРАТУРА


practice parameter. J Allergy Clin Immunol


2008;122(Suppl. 2):1–84.


6. Connell JT. Quantitative intranasal pollen challenge. II. Effect of daily pollen challenge, environmental pollen exposure, and placebo challenge on the nasal membrane. J Allergy


1968;41(3):123–39.


7. Connell JT. Quantitative intranasal pollen challenges. III. The priming effect in allergic rhinitis. J Allergy 1969;43(1):33–44.


8. Milanese M, et al. Eosinophils, specific hyperreactivity and occurrence of late phase reaction in allergic rhinitis. Eur Ann Allergy Clin Immunol 2005;37(1):7–10.


9. Bousquet J, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl. 86):


8–160.


10. Ariano R, et al. Possible role of climate changes






in variations in pollen seasons and allergic sensitizations during 27 years. Ann Allergy Asthma Immunol 2010;104(3):215–22.


11. Ziska L, et al. Recent warming by latitude associated with increased length of ragweed pollen season in central North America. Proc Natl Acad Sci USA 2011;108(10):4248–51.


12. Ellis AK, et al. Factors that affect the allergic rhinitis response to ragweed allergen exposure. Ann Allergy Asthma Immunol 2010;104(4):293–8.


13. Parker JD, et al. Air pollution and childhood respiratory allergies in the United States. Environ Health Perspect 2009;117(1):140–47.


14. Sehlstedt M, et al. Airway inflammatory response to diesel exhaust generated at urban cycle running conditions. Inhal Toxicol 2010;22(14):


1144–50.


15. Yoshizaki K, et al. Subchronic effects of nasally instilled diesel exhaust particulates on the nasal and airway epithelia in mice. Inhal Toxicol










2010;22(7):610–7.


16. Ciprandi G, et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995;96(6 pt 1):971–79.


17. Braunstahl GJ, et al. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001;107(3):469–76.


18. Pelikan Z. Asthmatic response induced by nasal challenge with allergen. Int Arch Allergy Immunol


2009;148(4):330–38.


19. Crystal-Peters J, et al. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol


2002;109(1):57–62.


20. Bousquet J, et al. Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol


2001;108(Suppl. 5):147–334.


21. Lack G, et al. The link between otitis media with effusion and allergy: a potential role for intranasal corticosteroids. Pediatr Allergy Immunol 2011;22(3):258–66.


22. Marple BF. Targeting congestion in allergic rhinitis:


the importance of intranasal corticosteroids.



Allergy Asthma Proc 2008;29(3):232–40.


23. Meltzer EO. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy. 1997;52(Suppl 36):33–40.


24. Frieri M, et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1998;81(5 pt 1):431–37.


25. Pitsios C, et al. Efficacy and safety of mometasone furoate vs nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol


2006;96(5):673–78.


26. Bousquet J, et al. Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray. A multicenter, double- blind, double-dummy, parallel-group study. Allergy 1993;48(5):327–33.


27. Juniper EF, et al. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 1989;83(3):627–33.


28. Blaiss MS. Safety considerations of intranasal corticosteroids for the treatment of allergic



rhinitis. Allergy Asthma Proc 2007;


28(2):145–52.


29. Meltzer EO, et al. Safety and tolerability of fluticasone furoate nasal spray once daily in paediatric patients aged 6-11 years with allergic rhinitis: subanalysis of three randomized, double-blind, placebo-controlled, multicentre studies. Clin Drug Investig 2009;


29(2):79–86.


30. Nasonex prescribing information. Whitehouse


Station, NJ: Merck & Co., Inc; 2011.


31. Veramyst prescribing information. Research


Triangle Park, NC: GlaxoSmithKline; 2011.


32. Bielory L, et al. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy


2011;66(5):686–93.


33. Baiardini I, et al. Effects of mometasone furoate on the quality of life: a randomized placebo-controlled trial in persistent allergic rhinitis and intermittent asthma using the Rhinasthma questionnaire. Clin Exp Allergy


2011;41(3):417–23.


34. Fromer L, et al. Assessment of patient attitudes about mometasone furoate nasal spray: The Ease-of-Use Patient Survey. World Allergy Organiz J 2008;1(9):156–59.


Похожие статьи


Бионика Медиа